All In Biotech

Drug Trial Radar · NCT02369146

To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

A Phase II, Open-label, Multiple-dose Trial to Investigate the Safety and Efficacy of UB-421 Monotherapy in Substitution for Stable Antiretroviral Therapy in HIV Infected Adults

Last checked: Nov 19, 2026Latest source record: Oct 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Jun 2015

Primary completion

Jul 2016

Study completion Jul 2016

Sponsor

Lead sponsor
United BioPharmaIndustry
Sponsor type
Industry
Collaborators
Taipei Veterans General Hospital, Taiwan; Kaohsiung Veterans General Hospital.; Kaohsiung Medical University Chung-Ho Memorial Hospital
First posted
Feb 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase II study is to evaluate the safety, tolerability and efficacy of two multi-dose regimens of UB-421 monotherapy in replacement of HAART in HIV-1 infected adults with virological suppression.

Conditions

  • HIV-1 Infection

Interventions

  • UB-421Drug

    The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: 17 weeks for cohort 1, 25 weeks for cohort 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.